Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2017 | 06-2017 | 03-2017 | 12-2016 | 09-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,130 | -3,945 | -1,704 | -6,369 | -3,845 |
| Depreciation Amortization | 102 | 73 | 40 | 304 | 227 |
| Accounts payable and accrued liabilities | 126 | 242 | 133 | -560 | -617 |
| Other Working Capital | 65 | -37 | -370 | -1,068 | -1,214 |
| Other Operating Activity | 926 | 458 | 40 | 2,319 | 1,430 |
| Operating Cash Flow | $-4,911 | $-3,210 | $-1,861 | $-5,375 | $-4,019 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -9 | -5 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $-9 | $-5 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 745 | N/A | N/A | 4,696 | 4,696 |
| Other Financing Activity | 3,872 | 3,872 | 0 | 0 | 0 |
| Financing Cash Flow | $4,617 | $3,872 | $N/A | $4,696 | $4,696 |
| Beginning Cash Position | 3,083 | 3,083 | 3,083 | 3,716 | 3,716 |
| End Cash Position | 2,789 | 3,745 | 1,222 | 3,028 | 4,388 |
| Net Cash Flow | $-294 | $662 | $-1,861 | $-688 | $672 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,911 | -3,210 | -1,861 | -5,375 | -4,019 |
| Capital Expenditure | N/A | N/A | N/A | -9 | -5 |
| Free Cash Flow | -4,911 | -3,210 | -1,861 | -5,384 | -4,024 |